12:00 AM
Apr 15, 2013
 |  BC Week In Review  |  Company News  |  Other News

VLST cancer, autoimmune, inflammation news

VLST said it would reduce headcount by 12 (70%) to five by year end to focus on cancer compound CP-870,893, which it licensed from Pfizer Inc. (NYSE:PFE, New York, N.Y.) in August....

Read the full 157 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Week In Review

Article Purchase

$35 USD
More Info >